ID   BUB1_HUMAN              Reviewed;        1085 AA.
AC   O43683; E9PC26; F5GXI5; O43430; O43643; O60626; Q53QE4;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1998, sequence version 1.
DT   22-JUL-2015, entry version 150.
DE   RecName: Full=Mitotic checkpoint serine/threonine-protein kinase BUB1;
DE            Short=hBUB1;
DE            EC=2.7.11.1;
DE   AltName: Full=BUB1A;
GN   Name=BUB1; Synonyms=BUB1L;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT TYR-492.
RX   PubMed=9521327; DOI=10.1038/32688;
RA   Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K.V.,
RA   Markowitz S.D., Kinzler K.W., Vogelstein B.;
RT   "Mutations of mitotic checkpoint genes in human cancers.";
RL   Nature 392:300-303(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9790499;
RA   Ouyang B., Lan Z., Meadows J., Pan H., Fukasawa K., Li W., Dai W.;
RT   "Human Bub1: a putative spindle checkpoint kinase closely linked to
RT   cell proliferation.";
RL   Cell Growth Differ. 9:877-885(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9660858; DOI=10.1083/jcb.142.1.1;
RA   Taylor S.S., Ha E., McKeon F.;
RT   "The human homologue of Bub3 is required for kinetochore localization
RT   of Bub1 and a Mad3/Bub1-related protein kinase.";
RL   J. Cell Biol. 142:1-11(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, PHOSPHORYLATION,
RP   INTERACTION WITH BUB3 AND MAD1L1, AND MUTAGENESIS OF LYS-821.
RC   TISSUE=Testis;
RX   PubMed=10198256; DOI=10.1006/bbrc.1999.0514;
RA   Seeley T.W., Wang L., Zhen J.Y.;
RT   "Phosphorylation of human MAD1 by the BUB1 kinase in vitro.";
RL   Biochem. Biophys. Res. Commun. 257:589-595(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANTS ASP-36 AND
RP   ARG-648.
RX   PubMed=10366450; DOI=10.1006/geno.1999.5831;
RA   Cahill D.P., da Costa L.T., Carson-Walter E.B., Kinzler K.W.,
RA   Vogelstein B., Lengauer C.;
RT   "Characterization of MAD2B and other mitotic spindle checkpoint
RT   genes.";
RL   Genomics 58:181-187(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 276-1085.
RX   PubMed=9441741; DOI=10.1006/geno.1997.5068;
RA   Pangilinan F., Li Q., Weaver T., Lewis B.C., Dang C.V., Spencer F.;
RT   "Mammalian BUB1 protein kinases: map positions and in vivo
RT   expression.";
RL   Genomics 46:379-388(1997).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15020684; DOI=10.1242/jcs.01006;
RA   Johnson V.L., Scott M.I., Holt S.V., Hussein D., Taylor S.S.;
RT   "Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-
RT   F and Mad2, and chromosome congression.";
RL   J. Cell Sci. 117:1577-1589(2004).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION, AND INTERACTION WITH BUB3.
RX   PubMed=15525512; DOI=10.1016/j.molcel.2004.09.031;
RA   Tang Z., Shu H., Oncel D., Chen S., Yu H.;
RT   "Phosphorylation of Cdc20 by Bub1 provides a catalytic mechanism for
RT   APC/C inhibition by the spindle checkpoint.";
RL   Mol. Cell 16:387-397(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=15723797; DOI=10.1016/j.cub.2004.12.044;
RA   Kitajima T.S., Hauf S., Ohsugi M., Yamamoto T., Watanabe Y.;
RT   "Human Bub1 defines the persistent cohesion site along the mitotic
RT   chromosome by affecting Shugoshin localization.";
RL   Curr. Biol. 15:353-359(2005).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH PLK1, PHOSPHORYLATION
RP   AT THR-609, AND MUTAGENESIS OF THR-609.
RX   PubMed=16760428; DOI=10.1091/mbc.E06-03-0240;
RA   Qi W., Tang Z., Yu H.;
RT   "Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is
RT   required for the kinetochore localization of Plk1.";
RL   Mol. Biol. Cell 17:3705-3716(2006).
RN   [14]
RP   SUBCELLULAR LOCATION, INTERACTION WITH CASC5, AND MUTAGENESIS OF
RP   ALA-106 AND LEU-122.
RX   PubMed=17981135; DOI=10.1016/j.devcel.2007.09.005;
RA   Kiyomitsu T., Obuse C., Yanagida M.;
RT   "Human Blinkin/AF15q14 is required for chromosome alignment and the
RT   mitotic checkpoint through direct interaction with Bub1 and BubR1.";
RL   Dev. Cell 13:663-676(2007).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION, DOMAIN KEN BOX, AND
RP   MUTAGENESIS OF LYS-535; GLU-536; ASN-537; LYS-625; GLU-626 AND
RP   ASN-627.
RX   PubMed=17158872; DOI=10.1074/jbc.M609376200;
RA   Qi W., Yu H.;
RT   "KEN-box-dependent degradation of the Bub1 spindle checkpoint kinase
RT   by the anaphase-promoting complex/cyclosome.";
RL   J. Biol. Chem. 282:3672-3679(2007).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-314, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-596 AND SER-655, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-593 AND SER-596, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [20]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN.
RX   PubMed=18922873; DOI=10.1128/JVI.01515-08;
RA   Hein J., Boichuk S., Wu J., Cheng Y., Freire R., Jat P.S.,
RA   Roberts T.M., Gjoerup O.V.;
RT   "Simian virus 40 large T antigen disrupts genome integrity and
RT   activates a DNA damage response via Bub1 binding.";
RL   J. Virol. 83:117-127(2009).
RN   [21]
RP   FUNCTION, MUTAGENESIS OF ALA-130, AND CHARACTERIZATION OF VARIANTS
RP   CYS-259 AND ASN-265.
RX   PubMed=19487456; DOI=10.1083/jcb.200902128;
RA   Klebig C., Korinth D., Meraldi P.;
RT   "Bub1 regulates chromosome segregation in a kinetochore-independent
RT   manner.";
RL   J. Cell Biol. 185:841-858(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-314; SER-375; SER-563;
RP   SER-596 AND SER-655, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-563; SER-593 AND
RP   SER-596, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-593 AND SER-596, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-596, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   VARIANTS PANCREATIC CANCER CYS-259 AND ASN-265.
RX   PubMed=12655561; DOI=10.1002/humu.9120;
RA   Hempen P.M., Kurpad H., Calhoun E.S., Abraham S., Kern S.E.;
RT   "A double missense variation of the BUB1 gene and a defective mitotic
RT   spindle checkpoint in the pancreatic cancer cell line Hs766T.";
RL   Hum. Mutat. 21:445-445(2003).
RN   [28]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-20 AND ASP-534.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that performs 2 crucial
CC       functions during mitosis: it is essential for spindle-assembly
CC       checkpoint signaling and for correct chromosome alignment. Has a
CC       key role in the assembly of checkpoint proteins at the
CC       kinetochore, being required for the subsequent localization of
CC       CENPF, BUB1B, CENPE and MAD2L1. Required for the kinetochore
CC       localization of PLK1. Plays an important role in defining SGOL1
CC       localization and thereby affects sister chromatid cohesion. Acts
CC       as a substrate for anaphase-promoting complex or cyclosome (APC/C)
CC       in complex with its activator CDH1 (APC/C-Cdh1). Necessary for
CC       ensuring proper chromosome segregation and binding to BUB3 is
CC       essential for this function. Can regulate chromosome segregation
CC       in a kinetochore-independent manner. Can phosphorylate BUB3. The
CC       BUB1-BUB3 complex plays a role in the inhibition of APC/C when
CC       spindle-assembly checkpoint is activated and inhibits the
CC       ubiquitin ligase activity of APC/C by phosphorylating its
CC       activator CDC20. This complex can also phosphorylate MAD1L1.
CC       Kinase activity is essential for inhibition of APC/CCDC20 and for
CC       chromosome alignment but does not play a major role in the
CC       spindle-assembly checkpoint activity. Mediates cell death in
CC       response to chromosome missegregation and acts to suppress
CC       spontaneous tumorigenesis. {ECO:0000269|PubMed:10198256,
CC       ECO:0000269|PubMed:15020684, ECO:0000269|PubMed:15525512,
CC       ECO:0000269|PubMed:15723797, ECO:0000269|PubMed:16760428,
CC       ECO:0000269|PubMed:17158872, ECO:0000269|PubMed:19487456}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Autophosphorylated when the cells enters
CC       mitosis.
CC   -!- SUBUNIT: Interacts with BUB3 and CASC5. Interacts (when
CC       phosphorylated) with PLK1. The BUB1-BUB3 complex interacts with
CC       MAD1L1. Interacts with SV40 Large T antigen; this interaction
CC       induces activation of a DNA damage response and promotes p53/TP53
CC       stabilization and phosphorylation (Probable).
CC       {ECO:0000305|PubMed:10198256, ECO:0000305|PubMed:15525512,
CC       ECO:0000305|PubMed:16760428, ECO:0000305|PubMed:17981135,
CC       ECO:0000305|PubMed:18922873}.
CC   -!- INTERACTION:
CC       P03070:- (xeno); NbExp=2; IntAct=EBI-748936, EBI-617698;
CC       O43684:BUB3; NbExp=4; IntAct=EBI-748936, EBI-1050987;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Chromosome, centromere,
CC       kinetochore. Note=Nuclear in interphase cells. Accumulates
CC       gradually during G1 and S phase of the cell cycle, peaks at G2/M,
CC       and drops dramatically after mitosis. Localizes to the outer
CC       kinetochore. Kinetochore localization is required for normal
CC       mitotic timing and checkpoint response to spindle damage and
CC       occurs very early in prophase. AURKB, CASC5 and INCENP are
CC       required for kinetochore localization (By similarity).
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O43683-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43683-2; Sequence=VSP_054761;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC       Name=3;
CC         IsoId=O43683-3; Sequence=VSP_054760;
CC         Note=No experimental confirmation available. Gene prediction
CC         based on EST data.;
CC   -!- TISSUE SPECIFICITY: High expression in testis and thymus, less in
CC       colon, spleen, lung and small intestine. Expressed in fetal
CC       thymus, bone marrow, heart, liver, spleen and thymus. Expression
CC       is associated with cells/tissues with a high mitotic index.
CC   -!- INDUCTION: Inhibited by phorbol 12-myristate 13-acetate (PMA).
CC   -!- DOMAIN: The KEN box is required for its ubiquitination and
CC       degradation. {ECO:0000269|PubMed:17158872}.
CC   -!- DOMAIN: BUB1 N-terminal domain directs kinetochore localization
CC       and binding to BUB3. {ECO:0000269|PubMed:17158872}.
CC   -!- PTM: Upon spindle-assembly checkpoint activation it is
CC       hyperphosphorylated and its kinase activity toward CDC20 is
CC       stimulated. Phosphorylation at Thr-609 is required for interaction
CC       with PLK1, phosphorylation at this site probably creates a binding
CC       site for the POLO-box domain of PLK1, thus enhancing the PLK1-BUB1
CC       interaction. {ECO:0000269|PubMed:10198256,
CC       ECO:0000269|PubMed:15525512, ECO:0000269|PubMed:16760428}.
CC   -!- PTM: Ubiquitinated and degraded during mitotic exit by APC/C-Cdh1.
CC       {ECO:0000269|PubMed:17158872}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. BUB1 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SIMILARITY: Contains 1 BUB1 N-terminal domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00822}.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BUB1ID853ch2q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF046078; AAC12729.1; -; mRNA.
DR   EMBL; AF043294; AAB97855.2; -; mRNA.
DR   EMBL; AF053305; AAC06259.1; -; mRNA.
DR   EMBL; AF047471; AAC03122.1; -; mRNA.
DR   EMBL; AF139363; AAD43675.1; -; Genomic_DNA.
DR   EMBL; AF139349; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139350; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139351; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139352; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139353; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139354; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139355; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139356; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139357; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139358; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139359; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139360; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139361; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AF139362; AAD43675.1; JOINED; Genomic_DNA.
DR   EMBL; AC114776; AAY14706.1; -; Genomic_DNA.
DR   EMBL; AC226101; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471237; EAW50355.1; -; Genomic_DNA.
DR   EMBL; BC028201; AAH28201.1; -; mRNA.
DR   EMBL; AF011387; AAC39546.1; -; mRNA.
DR   CCDS; CCDS33273.1; -. [O43683-1]
DR   CCDS; CCDS62984.1; -. [O43683-3]
DR   CCDS; CCDS62985.1; -. [O43683-2]
DR   RefSeq; NP_001265546.1; NM_001278617.1. [O43683-2]
DR   RefSeq; NP_004327.1; NM_004336.4. [O43683-1]
DR   UniGene; Hs.469649; -.
DR   PDB; 2LAH; NMR; -; A=1-150.
DR   PDB; 4A1G; X-ray; 2.60 A; A/B/C/D=1-150.
DR   PDB; 4QPM; X-ray; 2.20 A; A/B=740-1085.
DR   PDB; 4R8Q; X-ray; 2.31 A; A=724-1085.
DR   PDBsum; 2LAH; -.
DR   PDBsum; 4A1G; -.
DR   PDBsum; 4QPM; -.
DR   PDBsum; 4R8Q; -.
DR   ProteinModelPortal; O43683; -.
DR   SMR; O43683; 1-150, 740-1083.
DR   BioGrid; 107164; 34.
DR   DIP; DIP-24206N; -.
DR   IntAct; O43683; 75.
DR   MINT; MINT-1460788; -.
DR   STRING; 9606.ENSP00000302530; -.
DR   BindingDB; O43683; -.
DR   ChEMBL; CHEMBL1772932; -.
DR   GuidetoPHARMACOLOGY; 1949; -.
DR   PhosphoSite; O43683; -.
DR   BioMuta; BUB1; -.
DR   MaxQB; O43683; -.
DR   PaxDb; O43683; -.
DR   PRIDE; O43683; -.
DR   DNASU; 699; -.
DR   Ensembl; ENST00000302759; ENSP00000302530; ENSG00000169679.
DR   Ensembl; ENST00000409311; ENSP00000386701; ENSG00000169679. [O43683-2]
DR   Ensembl; ENST00000535254; ENSP00000441013; ENSG00000169679. [O43683-3]
DR   GeneID; 699; -.
DR   UCSC; uc002tgc.3; human. [O43683-1]
DR   CTD; 699; -.
DR   GeneCards; GC02M111395; -.
DR   HGNC; HGNC:1148; BUB1.
DR   HPA; HPA006123; -.
DR   MIM; 602452; gene.
DR   neXtProt; NX_O43683; -.
DR   Orphanet; 1052; Mosaic variegated aneuploidy syndrome.
DR   PharmGKB; PA81; -.
DR   eggNOG; NOG317001; -.
DR   GeneTree; ENSGT00520000055622; -.
DR   HOGENOM; HOG000231751; -.
DR   HOVERGEN; HBG003709; -.
DR   InParanoid; O43683; -.
DR   OMA; DPLDVYD; -.
DR   OrthoDB; EOG75F4FF; -.
DR   PhylomeDB; O43683; -.
DR   TreeFam; TF105455; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; REACT_150425; Resolution of Sister Chromatid Cohesion.
DR   Reactome; REACT_150471; Separation of Sister Chromatids.
DR   Reactome; REACT_355252; RHO GTPases Activate Formins.
DR   Reactome; REACT_682; Mitotic Prometaphase.
DR   SignaLink; O43683; -.
DR   ChiTaRS; BUB1; human.
DR   EvolutionaryTrace; O43683; -.
DR   GeneWiki; BUB1; -.
DR   GenomeRNAi; 699; -.
DR   NextBio; 2860; -.
DR   PRO; PR:O43683; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; O43683; -.
DR   CleanEx; HS_BUB1; -.
DR   ExpressionAtlas; O43683; baseline and differential.
DR   Genevisible; O43683; HS.
DR   GO; GO:0000777; C:condensed chromosome kinetochore; IDA:UniProtKB.
DR   GO; GO:0000942; C:condensed nuclear chromosome outer kinetochore; IDA:CACAO.
DR   GO; GO:0005737; C:cytoplasm; IDA:HPA.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000776; C:kinetochore; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
DR   GO; GO:0007059; P:chromosome segregation; IEA:UniProtKB-KW.
DR   GO; GO:0000278; P:mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0007093; P:mitotic cell cycle checkpoint; TAS:ProtInc.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0007094; P:mitotic spindle assembly checkpoint; TAS:ProtInc.
DR   GO; GO:2001244; P:positive regulation of intrinsic apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0051983; P:regulation of chromosome segregation; IMP:UniProtKB.
DR   GO; GO:0007063; P:regulation of sister chromatid cohesion; IDA:UniProtKB.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0071173; P:spindle assembly checkpoint; IDA:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR015661; Bub1/Mad3.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR013212; Mad3/Bub1_I.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR14030; PTHR14030; 1.
DR   Pfam; PF08311; Mad3_BUB1_I; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00777; Mad3_BUB1_I; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51489; BUB1_N; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell cycle; Cell division; Centromere; Chromosome;
KW   Chromosome partition; Complete proteome; Host-virus interaction;
KW   Kinase; Kinetochore; Mitosis; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN         1   1085       Mitotic checkpoint serine/threonine-
FT                                protein kinase BUB1.
FT                                /FTId=PRO_0000085671.
FT   DOMAIN       11    182       BUB1 N-terminal. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00822}.
FT   DOMAIN      787   1085       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     793    801       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        1    146       Necessary for kinetochore localization.
FT   REGION       99    132       Necessary for interaction with CASC5.
FT   REGION      229    256       Necessary for interaction with BUB3.
FT   REGION      458    476       Essential for loading of BUBR1, MAD1L1
FT                                and MAD2L1 to kinetochores.
FT   MOTIF        58     65       Nuclear localization signal.
FT                                {ECO:0000255}.
FT   MOTIF       535    537       KEN box 1.
FT   MOTIF       625    627       KEN box 2.
FT   ACT_SITE    917    917       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     821    821       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     314    314       Phosphoserine.
FT                                {ECO:0000269|PubMed:17525332,
FT                                ECO:0000269|PubMed:19369195}.
FT   MOD_RES     375    375       Phosphoserine.
FT                                {ECO:0000269|PubMed:19369195}.
FT   MOD_RES     563    563       Phosphoserine.
FT                                {ECO:0000269|PubMed:19369195,
FT                                ECO:0000269|PubMed:19690332}.
FT   MOD_RES     593    593       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231}.
FT   MOD_RES     596    596       Phosphoserine.
FT                                {ECO:0000269|PubMed:18669648,
FT                                ECO:0000269|PubMed:18691976,
FT                                ECO:0000269|PubMed:19369195,
FT                                ECO:0000269|PubMed:19690332,
FT                                ECO:0000269|PubMed:20068231,
FT                                ECO:0000269|PubMed:21406692}.
FT   MOD_RES     609    609       Phosphothreonine; by CDK1.
FT                                {ECO:0000269|PubMed:16760428}.
FT   MOD_RES     655    655       Phosphoserine.
FT                                {ECO:0000269|PubMed:18691976,
FT                                ECO:0000269|PubMed:19369195}.
FT   VAR_SEQ      10     29       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_054760.
FT   VAR_SEQ     876    932       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_054761.
FT   VARIANT      20     20       G -> D (in dbSNP:rs35890336).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040400.
FT   VARIANT      36     36       E -> D (in colorectal cancer;
FT                                dbSNP:rs1801328).
FT                                {ECO:0000269|PubMed:10366450}.
FT                                /FTId=VAR_008849.
FT   VARIANT     259    259       Y -> C (in pancreatic cancer; associated
FT                                with N-265; failure to rescue the
FT                                spindle-assembly checkpoint activity as a
FT                                result of a deficient recruitment of
FT                                MAD2L1 and BUBR1 to kinetochores;
FT                                efficient restoration of chromosome
FT                                congression; reduced binding to BUB3;
FT                                rescue of the ability of kinetochores to
FT                                bind SGOL1 and CENPF but not MCAK).
FT                                {ECO:0000269|PubMed:12655561,
FT                                ECO:0000269|PubMed:19487456}.
FT                                /FTId=VAR_015687.
FT   VARIANT     265    265       H -> N (in pancreatic cancer; associated
FT                                with C-259; complete rescue of the
FT                                spindle-assembly checkpoint activity;
FT                                increased rate of chromosome congression
FT                                errors). {ECO:0000269|PubMed:12655561,
FT                                ECO:0000269|PubMed:19487456}.
FT                                /FTId=VAR_015688.
FT   VARIANT     492    492       S -> Y (in colorectal cancer).
FT                                {ECO:0000269|PubMed:9521327}.
FT                                /FTId=VAR_008850.
FT   VARIANT     534    534       N -> D (in dbSNP:rs36109304).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040401.
FT   VARIANT     648    648       P -> R (in colorectal cancer).
FT                                {ECO:0000269|PubMed:10366450}.
FT                                /FTId=VAR_008851.
FT   MUTAGEN     106    106       A->D,W: Loss of interaction with CASC5.
FT                                {ECO:0000269|PubMed:17981135}.
FT   MUTAGEN     122    122       L->G: Loss of interaction with CASC5.
FT                                {ECO:0000269|PubMed:17981135}.
FT   MUTAGEN     130    130       A->S: Partial rescue of the spindle-
FT                                assembly checkpoint activity. Increased
FT                                rate of chromosome congression errors.
FT                                Impaired localization to kinetochores and
FT                                loss of kinetochore binding of CENPF,
FT                                SGOL1 and BUBR1 but not of MCAK, MAD1L1
FT                                or MAD2L1. {ECO:0000269|PubMed:19487456}.
FT   MUTAGEN     535    535       K->A: Loss of ubiquitination and CDH1-
FT                                dependent degradation; when associated
FT                                with A-536 and A-537.
FT                                {ECO:0000269|PubMed:17158872}.
FT   MUTAGEN     536    536       E->A: Loss of ubiquitination and CDH1-
FT                                dependent degradation; when associated
FT                                with A-535 and A-537.
FT                                {ECO:0000269|PubMed:17158872}.
FT   MUTAGEN     537    537       N->A: Loss of ubiquitination and CDH1-
FT                                dependent degradation; when associated
FT                                with A-535 and A-536.
FT                                {ECO:0000269|PubMed:17158872}.
FT   MUTAGEN     609    609       T->A: Diminished interaction with PLK1.
FT                                {ECO:0000269|PubMed:16760428}.
FT   MUTAGEN     625    625       K->A: Loss of ubiquitination and CDH1-
FT                                dependent degradation; when associated
FT                                with A-626 and A-627.
FT                                {ECO:0000269|PubMed:17158872}.
FT   MUTAGEN     626    626       E->A: Loss of ubiquitination and CDH1-
FT                                dependent degradation; when associated
FT                                with A-625 and A-627.
FT                                {ECO:0000269|PubMed:17158872}.
FT   MUTAGEN     627    627       N->A: Loss of ubiquitination and CDH1-
FT                                dependent degradation; when associated
FT                                with A-625 and A-626.
FT                                {ECO:0000269|PubMed:17158872}.
FT   MUTAGEN     821    821       K->A: Loss of activity.
FT                                {ECO:0000269|PubMed:10198256}.
FT   CONFLICT     70     70       S -> T (in Ref. 5; AAC06259).
FT                                {ECO:0000305}.
FT   CONFLICT    276    279       MKRK -> IRHE (in Ref. 9; AAC39546).
FT                                {ECO:0000305}.
FT   HELIX         3     14       {ECO:0000244|PDB:4A1G}.
FT   HELIX        23     35       {ECO:0000244|PDB:4A1G}.
FT   HELIX        43     56       {ECO:0000244|PDB:4A1G}.
FT   HELIX        60     62       {ECO:0000244|PDB:4A1G}.
FT   HELIX        66     76       {ECO:0000244|PDB:4A1G}.
FT   HELIX        82     90       {ECO:0000244|PDB:4A1G}.
FT   TURN         91     97       {ECO:0000244|PDB:4A1G}.
FT   HELIX        99    111       {ECO:0000244|PDB:4A1G}.
FT   HELIX       115    127       {ECO:0000244|PDB:4A1G}.
FT   HELIX       133    145       {ECO:0000244|PDB:4A1G}.
FT   STRAND      737    739       {ECO:0000244|PDB:4R8Q}.
FT   HELIX       744    752       {ECO:0000244|PDB:4QPM}.
FT   HELIX       758    760       {ECO:0000244|PDB:4QPM}.
FT   STRAND      764    766       {ECO:0000244|PDB:4QPM}.
FT   STRAND      778    782       {ECO:0000244|PDB:4QPM}.
FT   STRAND      785    795       {ECO:0000244|PDB:4QPM}.
FT   STRAND      797    805       {ECO:0000244|PDB:4QPM}.
FT   STRAND      817    825       {ECO:0000244|PDB:4QPM}.
FT   HELIX       828    840       {ECO:0000244|PDB:4QPM}.
FT   TURN        843    845       {ECO:0000244|PDB:4QPM}.
FT   HELIX       846    848       {ECO:0000244|PDB:4QPM}.
FT   STRAND      852    857       {ECO:0000244|PDB:4QPM}.
FT   STRAND      862    866       {ECO:0000244|PDB:4QPM}.
FT   HELIX       874    882       {ECO:0000244|PDB:4QPM}.
FT   HELIX       891    910       {ECO:0000244|PDB:4QPM}.
FT   HELIX       920    922       {ECO:0000244|PDB:4QPM}.
FT   STRAND      923    925       {ECO:0000244|PDB:4QPM}.
FT   HELIX       927    930       {ECO:0000244|PDB:4QPM}.
FT   STRAND      942    944       {ECO:0000244|PDB:4QPM}.
FT   HELIX       953    955       {ECO:0000244|PDB:4QPM}.
FT   STRAND      967    971       {ECO:0000244|PDB:4QPM}.
FT   HELIX       976    978       {ECO:0000244|PDB:4QPM}.
FT   HELIX       985   1000       {ECO:0000244|PDB:4QPM}.
FT   STRAND     1006   1009       {ECO:0000244|PDB:4QPM}.
FT   STRAND     1012   1015       {ECO:0000244|PDB:4QPM}.
FT   HELIX      1025   1036       {ECO:0000244|PDB:4QPM}.
FT   HELIX      1047   1061       {ECO:0000244|PDB:4QPM}.
FT   TURN       1063   1065       {ECO:0000244|PDB:4QPM}.
FT   HELIX      1066   1082       {ECO:0000244|PDB:4QPM}.
SQ   SEQUENCE   1085 AA;  122375 MW;  38AE5E1F88C53BDC CRC64;
     MDTPENVLQM LEAHMQSYKG NDPLGEWERY IQWVEENFPE NKEYLITLLE HLMKEFLDKK
     KYHNDPRFIS YCLKFAEYNS DLHQFFEFLY NHGIGTLSSP LYIAWAGHLE AQGELQHASA
     VLQRGIQNQA EPREFLQQQY RLFQTRLTET HLPAQARTSE PLHNVQVLNQ MITSKSNPGN
     NMACISKNQG SELSGVISSA CDKESNMERR VITISKSEYS VHSSLASKVD VEQVVMYCKE
     KLIRGESEFS FEELRAQKYN QRRKHEQWVN EDRHYMKRKE ANAFEEQLLK QKMDELHKKL
     HQVVETSHED LPASQERSEV NPARMGPSVG SQQELRAPCL PVTYQQTPVN MEKNPREAPP
     VVPPLANAIS AALVSPATSQ SIAPPVPLKA QTVTDSMFAV ASKDAGCVNK STHEFKPQSG
     AEIKEGCETH KVANTSSFHT TPNTSLGMVQ ATPSKVQPSP TVHTKEALGF IMNMFQAPTL
     PDISDDKDEW QSLDQNEDAF EAQFQKNVRS SGAWGVNKII SSLSSAFHVF EDGNKENYGL
     PQPKNKPTGA RTFGERSVSR LPSKPKEEVP HAEEFLDDST VWGIRCNKTL APSPKSPGDF
     TSAAQLASTP FHKLPVESVH ILEDKENVVA KQCTQATLDS CEENMVVPSR DGKFSPIQEK
     SPKQALSSHM YSASLLRLSQ PAAGGVLTCE AELGVEACRL TDTDAAIAED PPDAIAGLQA
     EWMQMSSLGT VDAPNFIVGN PWDDKLIFKL LSGLSKPVSS YPNTFEWQCK LPAIKPKTEF
     QLGSKLVYVH HLLGEGAFAQ VYEATQGDLN DAKNKQKFVL KVQKPANPWE FYIGTQLMER
     LKPSMQHMFM KFYSAHLFQN GSVLVGELYS YGTLLNAINL YKNTPEKVMP QGLVISFAMR
     MLYMIEQVHD CEIIHGDIKP DNFILGNGFL EQDDEDDLSA GLALIDLGQS IDMKLFPKGT
     IFTAKCETSG FQCVEMLSNK PWNYQIDYFG VAATVYCMLF GTYMKVKNEG GECKPEGLFR
     RLPHLDMWNE FFHVMLNIPD CHHLPSLDLL RQKLKKVFQQ HYTNKIRALR NRLIVLLLEC
     KRSRK
//
